Company intelligence / Profile preview

Protara Therapeutics

New York, New York, United Statesprotaratx.com ↗

Ownership: Public · TARA
Employees: ~33
Development stage: Phase 2

Overview

TARA-002 has shown promising results in Phase 2 trials with a 72% six-month landmark complete response rate across BCG exposures, 100% six-month landmark complete response rate in BCG-Unresponsive patients, and 64% six-month landmark complete response rate in BCG-Naïve patients for NMIBC. In the STARBORN-1 trial for lymphatic malformations, two of three pediatric patients achieved complete response after one dose of TARA-002[6][9].

Therapeutic areas: GastroenterologyOncologyRare Diseases
Modalities: Cell therapyPhospholipid substrate replacement therapy
Industry: Biotech

Drug pipeline

3 assets

choline

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $218.6M
Total revenue: $0
Enterprise value: $204.3M

Beyond the preview

Go deeper on Protara Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protara Therapeutics.

Explore the full profile